Company: JUNS
Filing Date: 2025-08-19
Form Type: 10-Q
Source: 0001641172-25-024684
Chunk: 23

Company: JUPITER NEUROSCIENCES, INC.
Filing Date: 2025-08-19
Form: 10-Q
Item: Item 8
Chunk 23
---
 period ended June 30, 2024 of $951,868.

25

Liquidity
and Capital Resources; Plan of Operations

Historically, we have financed
our operations primarily by selling common stock, convertible debt, and proceeds from our IPO.

We have generated no revenues
from product sales since inception, incurred a net loss of $3,781,832 for the six months ended June 30, 2025, accumulated negative cash
flows from operating activities totaling $1,891,263 during that same period, and have an accumulated deficit since inception totaling
$29,803,961. Accordingly, management has concluded there is substantial doubt regarding our ability to continue as a going concern for
a period of at least twelve months as a result of our historical recurring losses, negative operating cash flows from operations and our
dependence on external financings. In addition, the report of our external auditor with respect to their audit of our financial statements
as of and for the years ended December 31, 2024 and 2023, included in our 2024 Annual Report on Form 10-K, includes an explanatory paragraph
regarding our ability to continue as a going concern.

In order to achieve our business
plans and sustain operations, we will need to raise additional funds which may be from sources including, but not limited to, the
issuance of equity or debt securities, licensing of our intellectual property, or entering into other partnering agreements.  If
we are unable to raise additional funds when needed, we may be required to delay, reduce, or terminate some or all of our development
programs and clinical trials. However, there can also be no assurance that we will be able to raise additional funds on commercially reasonable
terms, if at all.

The timing, extent,
and terms of additional capital the requirements will be on many factors, including:

    ●
    the
    scope, rate of progress and costs of our drug delivery, preclinical development activities, laboratory testing and clinical trials
    for our drug candidate;

    ●
    the
    number and scope of clinical programs we decide to pursue;

    ●
    the
    scope and costs of manufacturing development and commercial manufacturing activities;

    ●
    the
    extent to which we acquire or in-license other drug candidate and technologies;

    ●
    the
    cost, timing and outcome of regulatory review of our drug candidate;

    ●
    the
    cost and timing of establishing sales and marketing capabilities,